{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:28:06Z","timestamp":1787027286519,"version":"build-2736575974"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>The Chinese government has assumed an increasingly prominent role in global health governance in recent years, yet the engagement of Chinese enterprises remains underexplored. Existing studies have largely focused on Beijing\u2019s major initiatives during the COVID-19 pandemic, overlooking the evolving role of Chinese enterprises as non-state actors. This article provides a comprehensive review of the participation of Chinese vaccine companies in the global aid market, with particular attention to their changing roles, underlying motivations, and persistent challenges as latecomers from the Global South. Drawing on around 80 industry and policy documents, publicly available datasets, and 10 semi-structured interviews with industry and government stakeholders, this study uses documentary synthesis and thematic analysis to show that COVID-19 marked a critical turning point, accelerating Chinese vaccine manufacturers\u2019 international engagement while exposing persistent structural barriers. Unlike earlier studies, this review shows that Chinese vaccine enterprises\u2019 engagement in the global aid market is shaped not only by strategic market ambitions and alignment with national public health priorities, but also by enduring structural constraints such as geopolitical tensions, institutional mistrust, talent shortages, and reputational vulnerabilities. By situating Chinese enterprises within broader debates on non-state actors in global health, the study advances existing literature and offers policy-relevant insights to strengthen their capacity and influence in promoting equitable vaccine access.<\/jats:p>","DOI":"10.3389\/fpubh.2025.1692140","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:28:49Z","timestamp":1764916129000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A critical review of Chinese vaccine enterprises in the global aid market: evolution, drivers, and structural constraints"],"prefix":"10.3389","volume":"13","author":[{"given":"Mengli","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"ref1","author":"Net","year":"2016"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2105\/AJPH.2021.306647","article-title":"The health silk road: how China adapts the belt and road initiative to the COVID-19 pandemic","volume":"112","author":"Huang","year":"2022","journal-title":"Am J Public Health"},{"key":"ref3","author":"Net","year":"2022"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1016\/S0140-6736(17)32898-2","article-title":"China\u2019s silk road and global health","volume":"390","author":"Tang","year":"2017","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1142\/S2377740020500013","article-title":"Toward a health silk road: China\u2019s proposal for Global Health cooperation","volume":"6","author":"Cao","year":"2020","journal-title":"China Q Int Strategic Stud"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4324\/9781315297255-16","article-title":"China\u2019s role in Global Health governance","volume-title":"Routledge Handbook on the Politics of Global Health","author":"Youde","year":"2018"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/asjcl.2022.30","article-title":"China\u2019s new Global Health governance","volume":"18","author":"Zhou","year":"2023","journal-title":"Asian J Comp Law"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3390\/healthcare10071276","article-title":"China\u2019s vaccine diplomacy and its implications for Global Health governance","volume":"10","author":"Liu","year":"2022","journal-title":"Healthcare"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/09692290.2022.2074514","article-title":"Political economy of vaccine diplomacy: explaining varying strategies of China, India, and Russia\u2019s COVID-19 vaccine diplomacy","volume":"30","author":"Suzuki","year":"2023","journal-title":"Rev Int Polit Econ"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17441692.2023.2185799","article-title":"China\u2019s health silk road construction during the COVID-19 pandemic","volume":"18","author":"Zeng","year":"2023","journal-title":"Glob Public Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/10670564.2021.1966894","article-title":"China\u2019s health silk road in the Middle East and North Africa amidst COVID-19 and a contested world order","volume":"31","author":"Zoubir","year":"2022","journal-title":"J Contemp China"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/0264-410X(94)90328-X","article-title":"The crisis in vaccine supply: a framework for action","volume":"12","author":"Batson","year":"1994","journal-title":"Vaccine"},{"key":"ref13","year":"2024"},{"key":"ref14","year":"2023"},{"key":"ref15","year":""},{"key":"ref16","year":"2024"},{"key":"ref17","year":"2024"},{"key":"ref18","year":"2024"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/ia\/iiae328","article-title":"Attention politics and China\u2019s role transformation in Global Health partnerships","volume":"101","author":"Ding","year":"2025","journal-title":"Int Aff"},{"key":"ref20","first-page":"12","volume-title":"Global Vaccine Market Report 2024","year":"2025"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17441692.2021.1987502","article-title":"COVAX and the rise of the \u2018super public private partnership\u2019 for Global Health","volume":"18","author":"Storeng","year":"2023","journal-title":"Glob Public Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1016\/S0140-6736(21)01367-2","article-title":"A beautiful idea: how COVAX has fallen short","volume":"397","author":"Usher","year":"2021","journal-title":"Lancet"},{"key":"ref23","year":"2014"},{"key":"ref24","year":"2021"},{"key":"ref25","year":"2022"},{"key":"ref26","year":"2021"},{"key":"ref27","year":"2021"},{"key":"ref28","year":"2020"},{"key":"ref29","year":"2022"},{"key":"ref30","author":"Daily","year":"2023"},{"key":"ref31","year":"2021"},{"key":"ref32","year":"2022"},{"key":"ref33","year":"2022"},{"key":"ref34","author":"News","year":"2021"},{"key":"ref35","year":"2021"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1017\/S0260210514000345","article-title":"The rise of companies from emerging Markets in Global Health Governance: opportunities and challenges","volume":"40","author":"Roemer-Mahler","year":"2014","journal-title":"Rev Int Stud"},{"key":"ref37","volume-title":"Quoted from an interview with senior executives of Chinese top vaccine companies","year":"2025"},{"key":"ref38","article-title":"Release of the \u201cChina vaccine industry international cooperation development report 2023\u201d: exploring overseas strategies of vaccine enterprises under new circumstances","author":"Net","year":"2023"},{"key":"ref39","author":"Net","year":"2025"},{"key":"ref40","year":"2024"},{"key":"ref41","year":"2011"},{"key":"ref42","year":"2019"},{"key":"ref43","year":"2021"},{"key":"ref44","year":"2020"},{"key":"ref45","year":"2021"},{"key":"ref46","year":"2021"},{"key":"ref47","year":"2020"},{"key":"ref48","year":"2021"},{"key":"ref49","year":"2021"},{"key":"ref50","first-page":"117","article-title":"Let vaccines benefit the world: the Mission of China\u2019s Sinovac","volume-title":"China Econ Weekly","author":"Sun","year":"2022"},{"key":"ref51","year":"2024"},{"key":"ref52","year":"2023"},{"key":"ref53","year":"2020"},{"key":"ref54","year":""},{"key":"ref55","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1163\/19426720-02203004","article-title":"The Bill and Melinda Gates Foundation and legitimacy in Global Health governance","volume":"22","author":"Harman","year":"2016","journal-title":"Glob Gov"},{"key":"ref56","year":"2024"},{"key":"ref57","year":"2021"},{"key":"ref58","volume-title":"Quoted from an interview with officials from relevant government departments","year":"2025"},{"key":"ref59","year":"2019"},{"key":"ref60","year":"2025"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1692140\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:28:51Z","timestamp":1764916131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1692140\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":60,"alternative-id":["10.3389\/fpubh.2025.1692140"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1692140","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"article-number":"1692140"}}